Key result
CYP2C19*17 allele linked to ~22-fold higher bleeding risk, while *2 or *3 alleles predict MACE.
Why the study?
Data on genetic and nongenetic factors affecting clopidogrel response in the Arab population are scarce.
Does the presence of CYP2C19 genetic variants affect the risk of bleeding and MACE in Arab patients undergoing PCI and receiving clopidogrel?
Population
254 Arab patients undergoing PCI and stent implantation receiving clopidogrel in Doha, Qatar
Comparison
CYP2C19*17, *2, and *3 allele carriers vs non-carriers
Design
Prospective cohort study
Follow-up
12 months
Authors
Loading...
May inform genotype-guided clopidogrel use in Arab PCI patients; extends evidence to this population but leaves open randomized confirmation.
Cohort (n=254)
No
Does the presence of CYP2C19 genetic variants affect the risk of bleeding and MACE in Arab patients undergoing PCI and receiving clopidogrel?
Odds Ratio: 21.6 (95% CI 4.8–96.8)
p-value: p=< 0.0001
In Arab patients undergoing PCI and receiving clopidogrel, the CYP2C19*17 allele is strongly associated with increased bleeding risk, while the *2 and *3 alleles are associated with increased MACE risk.
Ali et al. (2022) conducted a cohort in Percutaneous coronary intervention (n=254). CYP2C19*17 allele vs. Non-carriers was evaluated on Bleeding events (OR 21.6, 95% CI 4.8-96.8, p=< 0.0001). Carriage of the CYP2C19*17 allele was associated with an increased risk of bleeding (OR 21.6; 95% CI 4.8-96.8; P<0.0001), while CYP2C19*2 or *3 alleles were associated with increased MACE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: